NCT03409432: An ongoing trial by John Reneau
This trial is ongoing. It must report results 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03409432 |
|---|---|
| Title | A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 16, 2018 |
| Completion date | July 16, 2025 |
| Required reporting date | July 16, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |